Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-GSK sees smaller 2021 profit fall after Q2 beat

Wed, 28th Jul 2021 12:14

* Q2 adjusted EPS 28.1 pence vs forecast 19.9 pence

* Sees FY adj EPS at better end of guidance range
(Adds more detail, background, shares)

By Pushkala Aripaka

July 28 (Reuters) - GSK forecast a smaller drop in
2021 profit on Wednesday as the drugmaker beat second-quarter
earnings expectations, buoyed by a recovery in routine visits to
doctors as pandemic restrictions ease.

The British company, which is spinning off its consumer
health arm to focus on improving its pharmaceuticals business,
said it made adjusted earnings per share (EPS) of 28.1 pence in
the three months to the end of June on sales of 8.1 billion
pounds ($11.2 billion).

Analysts had on average expected adjusted EPS of 19.9 pence
on turnover of 7.56 billion pounds, according to a
company-compiled consensus https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus.

"We expect this positive momentum to continue through the
second half of the year driving us towards the better end of our
earnings guidance range for 2021, and meaningful performance
improvement in 2022," CEO Emma Walmsley said in a statement.

The world's biggest vaccines maker by sales has forecast
adjusted EPS will decline by a mid to high-single digit
percentage this year.

GSK shares, which lost a quarter of their value in 2020,
were up 1.4% to 1,419 pence at 1125 GMT.

Pressure to show sustainable growth has mounted on Walmsley
after years of underperformance at the pharmaceuticals business.
The company has also locked horns with activist investor Elliott
over its future after the spin-off next year.

GSK said it made 258 million pounds of quarterly sales from
its adjuvant used to boost the effectiveness of COVID-19
vaccines.

But it added that while immunisation campaigns were making
progress, there remained uncertainty over the impact of the
pandemic and sales of key shingles vaccine Shingrix were
recovering more slowly than expected outside the United States.

As a result, it forecast revenues from vaccines over the
full year would be broadly flat.

($1 = 0.7206 pounds)

(Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout
in London
Editing by Mark Potter)

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.